Erbitux Gets C-Code Reimbursement; Waits For Green Light On J-Code
Executive Summary
Bristol/ImClone's Erbitux will receive C-code hospital outpatient reimbursement by the Centers for Medicare & Medicaid Services, the company said April 27
You may also be interested in...
Erbitux Launch Benefits From EGFR Screening; 75%-80% Of Patients Positive
Screening prospective patients for expression of epidermal growth factor receptor will positively affect Erbitux' launch, ImClone said April 27
Erbitux Launch Benefits From EGFR Screening; 75%-80% Of Patients Positive
Screening prospective patients for expression of epidermal growth factor receptor will positively affect Erbitux' launch, ImClone said April 27
Bristol/ImClone Erbitux Launched At $600 Per Vial; $2,400 For Initial Dose
Bristol-Myers Squibb/Imclone's oncologic Erbitux launched Feb. 25 at an average wholesale price of $600 per 100 mg of cetuximab